Best-in-class
anticancer drug
HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
targeted therapy for unmet medical needs in cancer.
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
First-in-class drugs with continuous innovation and challenges.
PR CENTER
-
About the Progress of the...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t... -
Apealea completes Pre-NDA...
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th... -
Immunomic Therapeutics, E...
- Agreement of COVID-19 Vaccine Joint DevelopmentAccording to a foreign press reported at 5 o'clock in the morning, thre...
-
HLB Life Sciences Secures...
HLB Life Sciences announced that it has secured exclusive distribution rights for ASCOR, only FDA-approved ascorbic acid... -
HLB Global acquires Barab...
HLB Global said it has acquired 355,000 shares of Barabio, a developer of next-generation immuno-oncology drugs, (26,900... -
HLB Panagene Expands Diag...
HLB Panagene and its subsidiary BioSquare unveiled a strategic plan today to capture the global market for cancer and re...
-
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatin... -
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood vessels are formed from pre-existing ones and it is involv... -
Camrelizumab combined wit...
Sub-category:Esophageal or Gastric CancerCategory:Gastrointestinal (Noncolorectal) CancerMeeting:2019 ASCO Annual Meetin...